LKS Advises Raghava Life Sciences API Business Sale to RPG Active Pharma

• Raghava Life Sciences Private Limited transferred its Active Pharmaceutical Ingredients (API) business to RPG Active Pharma Limited.
• The transaction was structured as a slump sale, involving a subsidiary of RPG Life Sciences Limited.
• Lakshmikumaran & Sridharan Attorneys advised Raghava Life Sciences on the comprehensive deal, including drafting and finalizing all transaction documents.
• Khaitan & Co assisted RPG Life Sciences with the carve-out of its API business.
• The acquired API business features an EU-GMP approved manufacturing facility, a diversified product portfolio, and serves both regulated and emerging markets.

This particular transaction highlights the strategic use of a slump sale structure for transferring a significant Active Pharmaceutical Ingredients business, showcasing sophisticated legal advisory in India's dynamic pharmaceutical M&A landscape.

Raghava Life Sciences Private Limited has successfully divested its Active Pharmaceutical Ingredients (API) business, transferring the operations to RPG Active Pharma Limited. This strategic acquisition sees RPG Active Pharma, a a subsidiary of RPG Life Sciences Limited, expand its footprint in the pharmaceutical sector through a slump sale. The complex transaction, which involved the comprehensive transfer of a specialized manufacturing unit and its associated product portfolio, underscores the dynamic nature of India's pharmaceutical M&A landscape. Lakshmikumaran & Sridharan Attorneys provided extensive legal counsel to Raghava Life Sciences throughout the entire process, advising on the LKS advises Raghava Life Sciences API business sale.

The deal also saw Khaitan & Co playing a significant role, assisting RPG Life Sciences with the intricate carve-out of its API business, which subsequently became part of RPG Active Pharma. This multi-faceted transaction highlights the strategic maneuvering by both parties to optimize their respective business portfolios. The transfer of the Active Pharmaceutical Ingredients business represents a notable development for both the seller, streamlining its operations, and the buyer, enhancing its capabilities and market reach within the critical API segment.

The API business acquired by RPG Active Pharma is a highly differentiated organization, boasting both commercialized and development-stage products. These offerings cater to a broad spectrum of markets, including highly regulated regions and emerging economies, demonstrating a robust global presence. A cornerstone of the business's operational excellence is its EU-GMP approved manufacturing facility, which ensures adherence to stringent European Good Manufacturing Practices standards. This certification is crucial for accessing premium markets and maintaining high-quality production.

Furthermore, the transferred entity maintains a diversified product portfolio, providing a stable revenue base and mitigating risks associated with reliance on a single product line. Its proven regulatory capabilities are also a significant asset, facilitating compliance and market entry in various jurisdictions. RPG Active Pharma, in collaboration with InvAscent, a private equity firm specializing in the pharma and life sciences sectors, is strategically positioned to leverage these strengths. Their joint objective is to accelerate the commercialization of these valuable assets, broaden market access for the API products, and unlock the next phase of growth for the newly acquired business. This India pharmaceutical M&A deal is poised to enhance RPG Active Pharma's competitive edge.

The successful completion of this slump sale hinged on meticulous legal advisory and comprehensive documentation, a mandate expertly handled by Lakshmikumaran & Sridharan Attorneys for Raghava Life Sciences. Their team, led by Executive Partner Noorul Hassan, alongside Associate Partner Shipra Verma and Senior Associates Isana Laisram and Shrika C, provided end-to-end support. This involved the drafting, thorough review, negotiation, and finalization of all critical transaction documents. Key instruments included the Business Transfer Agreement, which outlined the terms of the transfer, the Disclosure Letter, detailing relevant information about the business, and Conveyance Deeds for asset transfer. Employee Release Documents were also crucial for managing the human capital aspect of the transition.

Beyond document management, the LKS team provided full assistance with the closing of the transaction, ensuring a seamless transition of ownership and operations. This particular transaction highlights the strategic use of a slump sale structure for transferring a significant Active Pharmaceutical Ingredients business, showcasing sophisticated legal advisory in India's dynamic pharmaceutical M&A landscape. The involvement of Khaitan & Co in assisting RPG Life Sciences with the RPG API business carve-out further underscores the intricate legal requirements and specialized expertise demanded by such large-scale Lakshmikumaran & Sridharan M&A pharma deals in the sector.

This transaction highlights the use of a slump sale structure for transferring an Active Pharmaceutical Ingredients (API) business in India, offering a precedent for M&A lawyers advising on similar sector-specific business transfers. It also showcases the expertise of Lakshmikumaran & Sridharan and Khaitan & Co in complex pharmaceutical sector deals.

Source: Original reporting via Bar & Bench